These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37079393)

  • 41. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
    Stuart ASV; Virta M; Williams K; Seppa I; Hartvickson R; Greenland M; Omoruyi E; Bastian AR; Haazen W; Salisch N; Gymnopoulou E; Callendret B; Faust SN; Snape MD; Heijnen E
    J Infect Dis; 2022 Dec; 227(1):71-82. PubMed ID: 36259542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.
    Scaggs Huang F; Bernstein DI; Slobod KS; Portner A; Takimoto T; Russell CJ; Meagher M; Jones BG; Sealy RE; Coleclough C; Branum K; Dickey M; Buschle K; McNeal M; Makowski M; Nakamura A; Hurwitz JL
    Hum Vaccin Immunother; 2021 Feb; 17(2):554-559. PubMed ID: 32750273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.
    McFarland EJ; Karron RA; Muresan P; Cunningham CK; Valentine ME; Perlowski C; Thumar B; Gnanashanmugam D; Siberry GK; Schappell E; Barr E; Rexroad V; Yogev R; Spector SA; Aziz M; Patel N; Cielo M; Luongo C; Collins PL; Buchholz UJ;
    J Infect Dis; 2018 Apr; 217(9):1347-1355. PubMed ID: 29509911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
    Cicconi P; Jones C; Sarkar E; Silva-Reyes L; Klenerman P; de Lara C; Hutchings C; Moris P; Janssens M; Fissette LA; Picciolato M; Leach A; Gonzalez-Lopez A; Dieussaert I; Snape MD
    Clin Infect Dis; 2020 May; 70(10):2073-2081. PubMed ID: 31340042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial.
    Verdijk P; van der Plas JL; van Brummelen EMJ; Jeeninga RE; de Haan CAM; Roestenberg M; Burggraaf J; Kamerling IMC
    Vaccine; 2020 Sep; 38(39):6088-6095. PubMed ID: 32718816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study.
    Spearman P; Jin H; Knopp K; Xiao P; Gingerich MC; Kidd J; Singh K; Tellier M; Radziewicz H; Wu S; McGregor M; Freda B; Wang Z; John SP; Villinger FJ; He B
    Sci Adv; 2023 Oct; 9(43):eadj7611. PubMed ID: 37878713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
    Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
    J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
    Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
    Tapia MD; Sow SO; Lyke KE; Haidara FC; Diallo F; Doumbia M; Traore A; Coulibaly F; Kodio M; Onwuchekwa U; Sztein MB; Wahid R; Campbell JD; Kieny MP; Moorthy V; Imoukhuede EB; Rampling T; Roman F; De Ryck I; Bellamy AR; Dally L; Mbaya OT; Ploquin A; Zhou Y; Stanley DA; Bailer R; Koup RA; Roederer M; Ledgerwood J; Hill AVS; Ballou WR; Sullivan N; Graham B; Levine MM
    Lancet Infect Dis; 2016 Jan; 16(1):31-42. PubMed ID: 26546548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
    Ascough S; Vlachantoni I; Kalyan M; Haijema BJ; Wallin-Weber S; Dijkstra-Tiekstra M; Ahmed MS; van Roosmalen M; Grimaldi R; Zhang Q; Leenhouts K; Openshaw PJ; Chiu C
    Am J Respir Crit Care Med; 2019 Aug; 200(4):481-492. PubMed ID: 30753101
    [No Abstract]   [Full Text] [Related]  

  • 54. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
    Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
    J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque.
    Jenkins T; Wang R; Harder O; Xue M; Chen P; Corry J; Walker C; Teng M; Mejias A; Ramilo O; Niewiesk S; Li J; Peeples ME
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
    Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
    Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
    Falloon J; Talbot HK; Curtis C; Ervin J; Krieger D; Dubovsky F; Takas T; Yu J; Yu L; Lambert SL; Villafana T; Esser MT
    Clin Vaccine Immunol; 2017 Sep; 24(9):. PubMed ID: 28679495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.